Bio News
GSK and Hansoh Pharma’s B7-H3-targeted ADC met its primary endpoint in a phase 3 trial for relapsed osteosarcoma. It significantly improved progression-free survival (PFS) compared with chemotherapy in patients who had received at least two prior treatments. Hansoh Pharma is preparing for approval in China, while GSK began a global phase 1b/2 trial last month.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
